Related Experiment Video

Updated: May 1, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K

Effects of atorvastatin in combination with ezetimibe on carotid atherosclerosis in elderly patients with

P Luo1, L Li2, L X Wang3

  • 1Department of Cardiology, Qilu Hospital of Shandong University, Jinan, China.

Genetics and Molecular Research : GMR
|April 17, 2014
PubMed

Insights

Combining atorvastatin with ezetimibe significantly reduces carotid intima-media thickness (CIMT) and high-sensitivity C-reactive protein (hsCRP) in elderly patients with hypercholesterolemia, offering better outcomes than atorvastatin alone.

Area of Science:

  • Cardiology
  • Pharmacology
  • Geriatrics

Background:

  • Hypercholesterolemia is a major risk factor for carotid atherosclerosis, particularly in elderly populations.
  • Statins like atorvastatin are primary treatments, but combination therapy may offer enhanced benefits.

Purpose of the Study:

  • To evaluate the efficacy of combining atorvastatin with ezetimibe in managing carotid atherosclerosis in elderly hypercholesterolemic patients.
  • To compare the effects of combination therapy versus atorvastatin monotherapy on key atherosclerosis markers.

Main Methods:

  • A randomized controlled trial involving 84 elderly patients with hypercholesterolemia and carotid atherosclerosis.
  • Patients were assigned to receive either atorvastatin alone (control) or atorvastatin plus ezetimibe (combined group) for 12 months.
  • Blood lipid profiles, high-sensitivity C-reactive protein (hsCRP), and carotid intima-media thickness (CIMT) were measured pre- and post-treatment.

Main Results:

  • Both treatment groups showed significant reductions in CIMT, LDL-C, and hsCRP levels post-treatment (P < 0.05).
  • The combined group exhibited a more pronounced significant decrease in CIMT, LDL-C, and hsCRP compared to the control group (P < 0.01).
  • Post-treatment levels of CIMT, LDL-C, and hsCRP were significantly different between the combined and control groups (P < 0.05).

Conclusions:

  • Combination therapy with atorvastatin and ezetimibe offers superior efficacy in reducing LDL-C and hsCRP levels.
  • This combination therapy demonstrates a significant positive impact on inhibiting the progression of carotid atherosclerosis in elderly hypercholesterolemic patients.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
400
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
444
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
611
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
948